Detalles de la búsqueda
1.
Effect of Selepressin vs Placebo on Ventilator- and Vasopressor-Free Days in Patients With Septic Shock: The SEPSIS-ACT Randomized Clinical Trial.
JAMA
; 322(15): 1476-1485, 2019 Oct 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31577035
2.
Selepressin, a novel selective vasopressin V1A agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients.
Crit Care
; 21(1): 213, 2017 08 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28807037
3.
A Selective V(1A) Receptor Agonist, Selepressin, Is Superior to Arginine Vasopressin and to Norepinephrine in Ovine Septic Shock.
Crit Care Med
; 44(1): 23-31, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26496451
4.
Study protocol of a randomised, double-blind, placebo-controlled, two-arm parallel-group, multi-centre phase 3 pivotal trial to investigate the efficacy and safety of recombinant human alkaline phosphatase for treatment of patients with sepsis-associated acute kidney injury.
BMJ Open
; 13(4): e065613, 2023 04 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37012016
5.
Cardiac and metabolic changes in long-term high fructose-fat fed rats with severe obesity and extensive intramyocardial lipid accumulation.
Am J Physiol Regul Integr Comp Physiol
; 298(6): R1560-70, 2010 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-20357025
6.
Rationale and Design of an Adaptive Phase 2b/3 Clinical Trial of Selepressin for Adults in Septic Shock. Selepressin Evaluation Programme for Sepsis-induced Shock-Adaptive Clinical Trial.
Ann Am Thorac Soc
; 15(2): 250-257, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29388815
7.
Pharmacological modulation of gap junction function with the novel compound rotigaptide: a promising new principle for prevention of arrhythmias.
Basic Clin Pharmacol Toxicol
; 101(4): 215-30, 2007 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-17845503
8.
The angiotensin type 1 receptor activates extracellular signal-regulated kinases 1 and 2 by G protein-dependent and -independent pathways in cardiac myocytes and langendorff-perfused hearts.
Basic Clin Pharmacol Toxicol
; 100(5): 289-95, 2007 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-17448113
9.
Differential extracellular signal-regulated kinases 1 and 2 activation by the angiotensin type 1 receptor supports distinct phenotypes of cardiac myocytes.
Basic Clin Pharmacol Toxicol
; 100(5): 296-301, 2007 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-17448114
10.
Designing phase 3 sepsis trials: application of learned experiences from critical care trials in acute heart failure.
J Intensive Care
; 4: 24, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27034779
11.
Rotigaptide (ZP123) reverts established atrial conduction velocity slowing.
Cell Commun Adhes
; 12(5-6): 271-8, 2005.
Artículo
en Inglés
| MEDLINE | ID: mdl-16531322
12.
Metabolic and cardiac changes in high cholesterol-fructose-fed rats.
J Pharmacol Toxicol Methods
; 61(3): 292-6, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-20172035
13.
Maintenance of intercellular coupling by the antiarrhythmic peptide rotigaptide suppresses arrhythmogenic discordant alternans.
Am J Physiol Heart Circ Physiol
; 294(1): H41-9, 2008 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-17982010
14.
Increasing gap junctional coupling: a tool for dissecting the role of gap junctions.
J Membr Biol
; 216(1): 23-35, 2007 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-17568971
15.
Treatment with the gap junction modifier rotigaptide (ZP123) reduces infarct size in rats with chronic myocardial infarction.
J Cardiovasc Pharmacol
; 47(2): 236-42, 2006 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-16495761
16.
Identification of ischemia-regulated phosphorylation sites in connexin43: A possible target for the antiarrhythmic peptide analogue rotigaptide (ZP123).
J Mol Cell Cardiol
; 40(6): 790-8, 2006 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-16678851
17.
Pharmacological stimulation of cardiac gap junction coupling does not affect ischemia-induced focal ventricular tachycardia or triggered activity in dogs.
Am J Physiol Heart Circ Physiol
; 288(2): H511-6, 2005 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-15650154
18.
Pharmacological characterization of the new stable antiarrhythmic peptide analog Ac-D-Tyr-D-Pro-D-Hyp-Gly-D-Ala-Gly-NH2 (ZP123): in vivo and in vitro studies.
J Pharmacol Exp Ther
; 306(3): 1191-9, 2003 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-12829724
19.
Anti-arrhythmic peptide N-3-(4-hydroxyphenyl)propionyl Pro-Hyp-Gly-Ala-Gly-OH reduces dispersion of action potential duration during ischemia/reperfusion in rabbit hearts.
J Cardiovasc Pharmacol
; 40(5): 770-9, 2002 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-12409986
20.
ZP123 increases gap junctional conductance and prevents reentrant ventricular tachycardia during myocardial ischemia in open chest dogs.
J Cardiovasc Electrophysiol
; 14(5): 510-20, 2003 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-12776869
Resultados
1 -
20
de 20
1
Próxima >
>>